View in EDS HTML Full Text PDF Full Text

NSUNs-driven dysregulation: the next frontier in targeted cancer therapy?

Saved in:
Bibliographic Details
Title: NSUNs-driven dysregulation: the next frontier in targeted cancer therapy?
Authors: Zhao Y; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, PR China.; Liaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation; Liaoning Cancer immune peptide drug Engineering Technology Research Center; China Medical University, Shenyang, PR China., Zhang Y; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, PR China.; Liaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation; Liaoning Cancer immune peptide drug Engineering Technology Research Center; China Medical University, Shenyang, PR China., Zhou H; Hepatobiliary Surgery Department, First Hospital of China Medical University, Shenyang, Liaoning Province, PR China., Zhang L; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, PR China.; Liaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation; Liaoning Cancer immune peptide drug Engineering Technology Research Center; China Medical University, Shenyang, PR China., Guo J; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, PR China.; Liaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation; Liaoning Cancer immune peptide drug Engineering Technology Research Center; China Medical University, Shenyang, PR China., Tan Y; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, PR China.; Liaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation; Liaoning Cancer immune peptide drug Engineering Technology Research Center; China Medical University, Shenyang, PR China., Wu T; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, PR China.; Liaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation; Liaoning Cancer immune peptide drug Engineering Technology Research Center; China Medical University, Shenyang, PR China., Peng Y; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, PR China.; Liaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation; Liaoning Cancer immune peptide drug Engineering Technology Research Center; China Medical University, Shenyang, PR China., Che Y; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, PR China.; Liaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation; Liaoning Cancer immune peptide drug Engineering Technology Research Center; China Medical University, Shenyang, PR China., Pei Z; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, PR China.; Liaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation; Liaoning Cancer immune peptide drug Engineering Technology Research Center; China Medical University, Shenyang, PR China., Li J; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, PR China.; Liaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation; Liaoning Cancer immune peptide drug Engineering Technology Research Center; China Medical University, Shenyang, PR China., Fu B; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, PR China.; Liaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation; Liaoning Cancer immune peptide drug Engineering Technology Research Center; China Medical University, Shenyang, PR China., Wei M; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, PR China. mjwei@cmu.edu.cn.; Liaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation; Liaoning Cancer immune peptide drug Engineering Technology Research Center; China Medical University, Shenyang, PR China. mjwei@cmu.edu.cn.; Shenyang Kangwei Medical Laboratory Analysis Co. LTD, Liaoning Province, Shenyang, PR China. mjwei@cmu.edu.cn., Wu G; Hepatobiliary Surgery Department, First Hospital of China Medical University, Shenyang, Liaoning Province, PR China. gangw@cmu.edu.cn., Hu X; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, PR China. huxy2022@cmu.edu.cn.; Liaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation; Liaoning Cancer immune peptide drug Engineering Technology Research Center; China Medical University, Shenyang, PR China. huxy2022@cmu.edu.cn.; Scientific experimental center, School of Pharmacy, China Medical University, Shenyang, PR China. huxy2022@cmu.edu.cn., Wu H; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, PR China. wuhz@cmu.edu.cn.; Liaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation; Liaoning Cancer immune peptide drug Engineering Technology Research Center; China Medical University, Shenyang, PR China. wuhz@cmu.edu.cn.; Scientific experimental center, School of Pharmacy, China Medical University, Shenyang, PR China. wuhz@cmu.edu.cn.
Source: Cell death & disease [Cell Death Dis] 2025 Dec 18; Vol. 16 (1), pp. 901. Date of Electronic Publication: 2025 Dec 18.
Publication Type: Journal Article; Review
Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101524092 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-4889 (Electronic) NLM ISO Abbreviation: Cell Death Dis Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41413017
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: NSUNs-driven dysregulation: the next frontier in targeted cancer therapy?
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Zhao+Y%22">Zhao Y</searchLink>; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, PR China.; Liaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation; Liaoning Cancer immune peptide drug Engineering Technology Research Center; China Medical University, Shenyang, PR China.<br /><searchLink fieldCode="AU" term="%22Zhang+Y%22">Zhang Y</searchLink>; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, PR China.; Liaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation; Liaoning Cancer immune peptide drug Engineering Technology Research Center; China Medical University, Shenyang, PR China.<br /><searchLink fieldCode="AU" term="%22Zhou+H%22">Zhou H</searchLink>; Hepatobiliary Surgery Department, First Hospital of China Medical University, Shenyang, Liaoning Province, PR China.<br /><searchLink fieldCode="AU" term="%22Zhang+L%22">Zhang L</searchLink>; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, PR China.; Liaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation; Liaoning Cancer immune peptide drug Engineering Technology Research Center; China Medical University, Shenyang, PR China.<br /><searchLink fieldCode="AU" term="%22Guo+J%22">Guo J</searchLink>; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, PR China.; Liaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation; Liaoning Cancer immune peptide drug Engineering Technology Research Center; China Medical University, Shenyang, PR China.<br /><searchLink fieldCode="AU" term="%22Tan+Y%22">Tan Y</searchLink>; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, PR China.; Liaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation; Liaoning Cancer immune peptide drug Engineering Technology Research Center; China Medical University, Shenyang, PR China.<br /><searchLink fieldCode="AU" term="%22Wu+T%22">Wu T</searchLink>; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, PR China.; Liaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation; Liaoning Cancer immune peptide drug Engineering Technology Research Center; China Medical University, Shenyang, PR China.<br /><searchLink fieldCode="AU" term="%22Peng+Y%22">Peng Y</searchLink>; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, PR China.; Liaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation; Liaoning Cancer immune peptide drug Engineering Technology Research Center; China Medical University, Shenyang, PR China.<br /><searchLink fieldCode="AU" term="%22Che+Y%22">Che Y</searchLink>; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, PR China.; Liaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation; Liaoning Cancer immune peptide drug Engineering Technology Research Center; China Medical University, Shenyang, PR China.<br /><searchLink fieldCode="AU" term="%22Pei+Z%22">Pei Z</searchLink>; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, PR China.; Liaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation; Liaoning Cancer immune peptide drug Engineering Technology Research Center; China Medical University, Shenyang, PR China.<br /><searchLink fieldCode="AU" term="%22Li+J%22">Li J</searchLink>; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, PR China.; Liaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation; Liaoning Cancer immune peptide drug Engineering Technology Research Center; China Medical University, Shenyang, PR China.<br /><searchLink fieldCode="AU" term="%22Fu+B%22">Fu B</searchLink>; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, PR China.; Liaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation; Liaoning Cancer immune peptide drug Engineering Technology Research Center; China Medical University, Shenyang, PR China.<br /><searchLink fieldCode="AU" term="%22Wei+M%22">Wei M</searchLink>; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, PR China. mjwei@cmu.edu.cn.; Liaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation; Liaoning Cancer immune peptide drug Engineering Technology Research Center; China Medical University, Shenyang, PR China. mjwei@cmu.edu.cn.; Shenyang Kangwei Medical Laboratory Analysis Co. LTD, Liaoning Province, Shenyang, PR China. mjwei@cmu.edu.cn.<br /><searchLink fieldCode="AU" term="%22Wu+G%22">Wu G</searchLink>; Hepatobiliary Surgery Department, First Hospital of China Medical University, Shenyang, Liaoning Province, PR China. gangw@cmu.edu.cn.<br /><searchLink fieldCode="AU" term="%22Hu+X%22">Hu X</searchLink>; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, PR China. huxy2022@cmu.edu.cn.; Liaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation; Liaoning Cancer immune peptide drug Engineering Technology Research Center; China Medical University, Shenyang, PR China. huxy2022@cmu.edu.cn.; Scientific experimental center, School of Pharmacy, China Medical University, Shenyang, PR China. huxy2022@cmu.edu.cn.<br /><searchLink fieldCode="AU" term="%22Wu+H%22">Wu H</searchLink>; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, PR China. wuhz@cmu.edu.cn.; Liaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation; Liaoning Cancer immune peptide drug Engineering Technology Research Center; China Medical University, Shenyang, PR China. wuhz@cmu.edu.cn.; Scientific experimental center, School of Pharmacy, China Medical University, Shenyang, PR China. wuhz@cmu.edu.cn.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101524092%22">Cell death & disease</searchLink> [Cell Death Dis] 2025 Dec 18; Vol. 16 (1), pp. 901. <i>Date of Electronic Publication: </i>2025 Dec 18.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Review
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Pub%2E+Group%22">Nature Pub. Group </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101524092 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2041-4889 (Electronic) <i>NLM ISO Abbreviation: </i>Cell Death Dis <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41413017
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s41419-025-08269-6
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 901
    Titles:
      – TitleFull: NSUNs-driven dysregulation: the next frontier in targeted cancer therapy?
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Zhao Y
      – PersonEntity:
          Name:
            NameFull: Zhang Y
      – PersonEntity:
          Name:
            NameFull: Zhou H
      – PersonEntity:
          Name:
            NameFull: Zhang L
      – PersonEntity:
          Name:
            NameFull: Guo J
      – PersonEntity:
          Name:
            NameFull: Tan Y
      – PersonEntity:
          Name:
            NameFull: Wu T
      – PersonEntity:
          Name:
            NameFull: Peng Y
      – PersonEntity:
          Name:
            NameFull: Che Y
      – PersonEntity:
          Name:
            NameFull: Pei Z
      – PersonEntity:
          Name:
            NameFull: Li J
      – PersonEntity:
          Name:
            NameFull: Fu B
      – PersonEntity:
          Name:
            NameFull: Wei M
      – PersonEntity:
          Name:
            NameFull: Wu G
      – PersonEntity:
          Name:
            NameFull: Hu X
      – PersonEntity:
          Name:
            NameFull: Wu H
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 18
              M: 12
              Text: 2025 Dec 18
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 2041-4889
          Numbering:
            – Type: volume
              Value: 16
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Cell death & disease
              Type: main
ResultId 1